DEXCOM INC — Director's Dealing 2018

Oct 16, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2018-10-12

Reporting Person: Balo Andrew K (EVP, Reg. Strategy, Clinical)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-12	Common Stock	S	2991	$124.4854	Disposed	85114	Direct
2018-10-12	Common Stock	S	2009	$125.2353	Disposed	83105	Direct

Footnotes

F1: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: This transaction was executed in multiple trades at prices ranging from $124.00 to $124.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019.

F4: This transaction was executed in multiple trades at prices ranging from $125.02 to $125.30. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.